Currently, COPD-marketed therapy leaders include GSK’s Trelegy Ellipta, which is set to grow in sales to $2.16bn by 2033.

Patients with COPD and type 2 diabetes using SGLT2i were much less likely to have ER visits and hospitalizations related to COPD exacerbations.

Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, ...

The case was dealt with in the Single Justice Procedure, a secretive fast-track courts system which the government is under ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, ...

The European Commission has become the first regulator worldwide to approve Sanofi and Regeneron’s IL-4 and IL-13 inhibitor ... showed signs of efficacy in COPD in a mid-stage trial that also ...

A number of research tools have been combined to study smokers with a range of COPD severities classified according to the GOLD criteria. Methods: Sixty five subjects (11 healthy smokers, 44 smokers ...

More doctors are ordering bioAffinity Technologies' CyPath Lung test and sales are skyrocketing. A long-term military health ...

There are several tests that doctors can use to diagnose and monitor COPD. Let's take a look at what abnormal values for ...

Chronic obstructive pulmonary disease is one of the world’s leading causes of death - more than 300 million live with the ...

I am a 62-year-old female who has focal segmental glomerulosclerosis (FSGS) that was diagnosed in 2001. After several years ...